Buprenorphine and naloxone and Naltrexone interaction

Buprenorphine and naloxone and Naltrexone: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.

Major

Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.

What the FDA labels say

From the Buprenorphine and naloxone label · effective 2026-06-16

Major

Buprenorphine and naloxone sublingual tablet is contraindicated in patients with a history of hypersensitivity to buprenorphine or naloxone as serious adverse reactions, including anaphylactic shock, have been reported [see Warnings and Precautions (5.9) ] .

Contraindicationsby drug classView label on DailyMed
Major

Hypersensitivity to buprenorphine or naloxone.

Contraindicationsby drug classView label on DailyMed
Major

Use in Patients with Impaired Hepatic Function Buprenorphine/naloxone products are not recommended in patients with severe hepatic impairment and may not be appropriate for patients with moderate hepatic impairment.

Warnings and precautionsby drug classView label on DailyMed
Major

However, buprenorphine/naloxone products are not recommended for initiation of treatment (induction) in patients with moderate hepatic impairment due to the increased risk of precipitated withdrawal.

Warnings and precautionsby drug classView label on DailyMed
Major

If a CYP3A4 inducer is discontinued, consider buprenorphine and naloxone sublingual tablet dosage reduction and monitor for signs of respiratory depression.

Drug interactionsby drug classView label on DailyMed

From the Naltrexone label · effective 2026-01-30

Major

Any individual who has failed the naloxone challenge test or has a positive urine screen for opioids [see Warnings and Precautions ( 5.3 ) ] .

Contraindicationsnames Buprenorphine and naloxoneView label on DailyMed
Major

Any individual who has failed the naloxone challenge test or has a positive urine screen for opioids (4) .

Contraindicationsnames Buprenorphine and naloxoneView label on DailyMed
Major

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] .

Contraindicationsby drug classView label on DailyMed
Major

Patients with current physiologic opioid dependence [see Warnings and Precautions ( 5.3 ) ] .

Contraindicationsby drug classView label on DailyMed
Major

Patients in acute opioid withdrawal [see Warnings and Precautions ( 5.3 ) ] .

Contraindicationsby drug classView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.